Initial choice of oral glucose-lowering medication for diabetes mellitus: A patient-centered comparative effectiveness study

JAMA Internal Medicine

Volumn 174, Issue 12, 2014, Pages 1955-1962

  Berkowitz, Seth A ^a,b   Krumme, Alexis A ^a   Avorn, Jerry ^a   Brennan, Troyen ^c   Matlin, Olga S ^c   Spettell, Claire M ^d   Pezalla, Edmund J ^d   Brill, Gregory ^a   Shrank, William H ^c   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CVS Caremark   (United States)

^d AETNA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; MEGLITINIDE; METFORMIN; PRAMLINTIDE; SULFONYLUREA; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG EFFICACY; EDUCATIONAL STATUS; ETHNICITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; UNSTABLE ANGINA PECTORIS; AGED; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRESCRIPTION; PROCEDURES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK; STANDARDS; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ADULT; AGED; COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; ODDS RATIO; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84919492224     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.5294     Document Type: Article

References (28)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Dept of Health and Human Services; 2014.
2. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37(suppl 1):S14-S80.
3. Qaseem A, Humphrey LL, Sweet DE, StarkeyM, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218-231.
4. Bennett WL,Wilson LM, Bolen S, et al. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
6. Hong J, Zhang Y, Lai S, et al; SPREAD-DIMCAD Investigators. Effects ofmetformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304-1311.
7. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: ameta-analysis of randomised controlled trials. PLoS Med. 2012;9(4): e1001204.
8. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: ameta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221-228.
9. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-613.
10. Desai NR, Shrank WH, Fischer MA, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012;125(3):e1-e7.
11. Grant RW, Pabon-Nau L, Ross KM, Youatt EJ, Pandiscio JC, Park ER. Diabetes oral medication initiation and intensification: patient views compared with current treatment guidelines. Diabetes Educ. 2011;37(1):78-84.
12. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30(10):2478-2483.
13. Food and Drug Administration. Byetta-Label and Approval History. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?CFID=34450006&CFTOKEN=ed70a376f72834f9-62B65790-B0FB-077D-CA6B7E5F52D6A221#apphist. Accessed July 17, 2014.
14. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2014. Oslo, Sweden: WHO Collaborating Centre for Drug Statistics Methodology; 2013.
15. Menchine MD, Wiechmann W, Peters AL, Arora S. Trends in diabetes-related visits to US EDs from 1997 to 2007. Am J Emerg Med. 2012;30(5):754-758.
16. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.
17. Spreeuwenberg MD, Bartak A, Croon MA, et al. The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care. 2010;48(2):166-174.
18. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512-516.
19. Glynn RJ, Monane M, Gurwitz JH, Choodnovskiy I, Avorn J. Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. Am J Epidemiol. 1999;149(6):541-549.
20. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
21. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014;37(5):1367-1374.
22. Mayor S. European drug regulators publish their evaluation of rosiglitazone. BMJ. 2010;341: c7278.
23. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(suppl 2):S127-S138.
24. PeyrotM, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679.
25. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359 (15):1577-1589.
26. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157(9):601-610.
27. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298(22):2634-2643.
28. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2008;14(6):523-531.